<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425112</url>
  </required_header>
  <id_info>
    <org_study_id>31234EH</org_study_id>
    <nct_id>NCT01425112</nct_id>
  </id_info>
  <brief_title>Comparison of Subconjuctival Versus Topical Bevacizumab as Adjunct Therapy to Trabeculectomy</brief_title>
  <official_title>Clinical Trial Comparing Subconjunctival and Topical Bevacizumab as Adjuncts to Trabeculectomy in Improving Outcomes for Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sudhalkar Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sudhalkar Eye Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bevacizumab is an anti vascular endothelial growth factor(anti-VEGF) substance that is known
      to reduce neovascularization and fibrovascular proliferation in inflammatory conditions,
      including post-operative inflammation. It has shown efficacy in numerous ocular
      conditions(off-label), that includes Age related macular degeneration, proliferative diabetic
      retinopathy, neovascular glaucoma and corneal neovascularization. It is being explored as an
      option for preventing recurrence of pterygium and as an adjunct to improving outcomes of
      trabeculectomy. There is a debate as to the mode and duration of bevacizumab administration
      for trabeculectomy. This study aims to compare a single subconjunctival dose of bevacizumab
      with topical therapy over one month in terms of outcomes of trabeculectomy surgery,
      non-progression of field loss and stable intraocular pressure(IOP) control.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure control</measure>
    <time_frame>For 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Complications of Treatment</condition>
  <condition>Progression</condition>
  <arm_group>
    <arm_group_label>Topical/Subconjunctival</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Depending upon the mode of administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Phacoemulsification</intervention_name>
    <description>Surgery for complications of trabeculectomy</description>
    <arm_group_label>Topical/Subconjunctival</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary Open Angle Glaucoma

          -  Progression

          -  Failure to reach target IOP

          -  Non compliant

        Exclusion Criteria:

          -  Resurgery

          -  Systemic contraindication to bevacizumab

          -  All other forms of glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>August 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2011</study_first_posted>
  <last_update_submitted>August 26, 2011</last_update_submitted>
  <last_update_submitted_qc>August 26, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sudhalkar Eye Hospital</investigator_affiliation>
    <investigator_full_name>Aditya Sudhalkar</investigator_full_name>
    <investigator_title>Dr. Aditya Anand Sudhalkar</investigator_title>
  </responsible_party>
  <keyword>trabeculectomy</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>anti-VEGF</keyword>
  <keyword>Efficacy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

